URGN NASDAQ
UroGen Pharma Ltd.
1W: +0.7%
1M: +14.7%
3M: +41.8%
YTD: +31.6%
1Y: +296.3%
3Y: +154.3%
5Y: +96.6%
$28.89
-0.99 (-3.31%)
Weekly Expected Move ±11.5%
$22
$25
$29
$32
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (37)
Top global stories this week: Alibaba, Tencent among major names
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
UroGen (URGN) Q1 2026 Earnings Transcript
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen outlines ZUSDURI path to “peak annual revenues exceeding $1 billion” while holding 2026 operating expense guidance at $240M-$250M
Earnings Scheduled For May 6, 2026
UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
UroGen Pharma GAAP EPS of -$0.47 beats by $0.01, revenue of $51M beats by $6.18M
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Here are the major earnings before the open Wednesday
UroGen Pharma Q1 2026 Earnings Preview
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
Urogen Pharma $URGN Shares Sold by ARK Investment Management LLC
UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline
UroGen (URGN) Q4 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
UroGen Pharma GAAP EPS of -$0.54 misses by $0.03, revenue of $37.84M misses by $2.08M
UroGen Pharma: Q4 Earnings Insights
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
Earnings Scheduled For March 2, 2026
Here are the major earnings before the open Monday
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Urogen Pharma $URGN Shares Bought by Truist Financial Corp
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference